BIOCRYST PHARMACEUTICALS INC's ticker is BCRX and the CUSIP is 09058V103. A total of 236 filers reported holding BIOCRYST PHARMACEUTICALS INC in Q3 2022. The put-call ratio across all filers is 0.39 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2024 | $84,666 | +405.0% | 13,700 | +315.2% | 0.00% | +200.0% |
| Q1 2024 | $16,764 | +79728.6% | 3,300 | -5.7% | 0.00% | 0.0% |
| Q4 2023 | $21 | -95.4% | 3,500 | -94.6% | 0.00% | -94.7% |
| Q3 2023 | $457 | +125.1% | 64,600 | +124.3% | 0.02% | +72.7% |
| Q2 2023 | $203 | +16.0% | 28,800 | +37.1% | 0.01% | 0.0% |
| Q1 2023 | $175 | -46.6% | 21,000 | -26.6% | 0.01% | -54.2% |
| Q4 2022 | $328 | -99.6% | 28,600 | +333.3% | 0.02% | +200.0% |
| Q3 2022 | $83,000 | +654.5% | 6,600 | +560.0% | 0.01% | +100.0% |
| Q2 2022 | $11,000 | – | 1,000 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| RP Management, LLC | 3,846,154 | $40,692,000 | 16.07% |
| Fairmount Funds Management LLC | 3,343,107 | $35,370,000 | 8.10% |
| Kynam Capital Management, LP | 936,563 | $9,909,000 | 2.53% |
| Velan Capital Investment Management LP | 225,000 | $2,381,000 | 2.42% |
| ORACLE INVESTMENT MANAGEMENT INC | 603,994 | $6,390,000 | 1.94% |
| TANG CAPITAL MANAGEMENT LLC | 1,200,000 | $12,696,000 | 1.93% |
| MPM BioImpact LLC | 639,089 | $6,762,000 | 1.88% |
| Ghost Tree Capital, LLC | 325,000 | $3,439,000 | 1.79% |
| Sarissa Capital Management LP | 1,390,790 | $14,715,000 | 1.48% |
| Prosight Management, LP | 176,680 | $1,869,000 | 1.47% |